{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T20:19:42Z","timestamp":1783369182694,"version":"3.54.6"},"reference-count":18,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Objetivo: Determinar la frecuencia de sensibilizaci\u00f3n a polietilenglicol y\/o polisorbato en pacientes al\u00e9rgicos, con esquema de vacunaci\u00f3n completo contra COVID-19, que manifestaron reacciones adversas sist\u00e9micas.\nM\u00e9todos: Estudio transversal, descriptivo, observacional y prolectivo, llevado a cabo en pacientes al\u00e9rgicos, de 18 a 60 a\u00f1os, con esquema de vacunaci\u00f3n completo contra COVID-19, con reacciones adversas sist\u00e9micas. Se realizaron pruebas cut\u00e1neas con polietilenglicol 2000 y polisorbato 80. Los resultados se analizaron mediante el c\u00e1lculo de promedios, porcentajes y frecuencias.\nResultados: Se registraron 55 pacientes (74.5% mujeres), con promedio de edad de 31.4 (DE 11.6). El diagn\u00f3stico alergol\u00f3gico m\u00e1s prevalente fue rinitis al\u00e9rgica, las reacciones adversas fueron tard\u00edas en 54 pacientes, report\u00e1ndose mialgias como la m\u00e1s com\u00fan. Se encontr\u00f3 sensibilizaci\u00f3n en 40%, de estos 32.7% fueron positivos a polisorbato 80. Las vacunas con mayor prevalencia de sensibilizaci\u00f3n fueron AstraZeneca y Sputnik. Aparecieron reacciones adversas durante las pruebas cut\u00e1neas en 5 pacientes y el evento adverso m\u00e1s frecuente fue cefalea.\nConclusiones: Se encontr\u00f3 alta frecuencia de sensibilizaci\u00f3n a polietilenglicol 2000 y polisorbato 80. En los pacientes sensibilizados se pueden recomendar alternativas con vacunas que no contengan los excipientes a los que resultaron positivos con el fin de evitar el riesgo de eventos adversos posteriores.\nPalabras clave: Polietilenglicol; Polisorbato; Vacunaci\u00f3n; COVID-19; Prueba cut\u00e1nea; Rinitis al\u00e9rgica; Mialgias.<\/jats:p>","DOI":"10.29262\/ram.v72i4.1535","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:31:05Z","timestamp":1767828665000},"page":"305-311","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Sensibilizaci\u00f3n a polietilenglicol y polisorbato en pacientes al\u00e9rgicos con reacciones adversas sist\u00e9micas posterior a la vacunaci\u00f3n contra COVID-19 &lt;\/b&gt;","&lt;b&gt;Sensitization to polyethylene glycol and polysorbate in allergic patients with systemic adverse reactions following COVID-19 vaccination &lt;\/b&gt;"],"prefix":"10.29262","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-9057","authenticated-orcid":false,"given":"Edgar","family":"Flores Gonzaga","sequence":"first","affiliation":[{"name":"Hospital Universitario de Puebla, Puebla, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-3006","authenticated-orcid":false,"given":"Chrystopherson","family":"Caballero L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Puebla, Puebla, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-5566","authenticated-orcid":false,"given":"A\u00edda In\u00e9s","family":"L\u00f3pez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Puebla, Puebla, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7586-2276","authenticated-orcid":false,"given":"Daniela","family":"Rivero Yeverino","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Puebla, Puebla, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-1575","authenticated-orcid":false,"given":"Juan Jes\u00fas","family":"R\u00edos L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Puebla, Puebla, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-5413","authenticated-orcid":false,"given":"Jos\u00e9 Sergio","family":"Papaqui Tapia","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Puebla, Puebla, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-7170","authenticated-orcid":false,"given":"Dulce Mariel","family":"Ruiz S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Puebla, Puebla, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-1535","authenticated-orcid":false,"given":"Armando","family":"Alvarez Rivera","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Puebla, Puebla, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5728-3644","authenticated-orcid":false,"given":"Elisa","family":"Ortega Jord\u00e1- Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Puebla, Puebla, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-6355","authenticated-orcid":false,"given":"Erika","family":"Villada Villada","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Puebla, Puebla, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11808","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"65288","doi-asserted-by":"crossref","unstructured":"1. D\u00edaz FJ. SARS-CoV-2\/COVID-19: el virus, la enfermedad y la pandemia. Medicina y laboratorio. 2020; 24 (3):183-205.","DOI":"10.36384\/01232576.268"},{"key":"65289","doi-asserted-by":"crossref","unstructured":"2. Aburto J, Romero J, Lucio C, et al. Mexico\u2019s response to COVID-19 epidemic (SARS-CoV-2) and the recommendations to the National Donation and Transplant Subsystem. Rev Mex Traspl. 2020; 9 (1): 6-14.","DOI":"10.35366\/94024"},{"key":"65290","doi-asserted-by":"crossref","unstructured":"3. Rutkowski K, Mirakian R, Till S, et al. Adverse reactions to COVID-19 vaccines: A practical approach. Clin Exp Allergy. 2021; 1 (10): 1\u20138.","DOI":"10.1111\/cea.13880"},{"key":"65291","doi-asserted-by":"crossref","unstructured":"4. Sampath V. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy. 2021; 76 (6): 1640-1660.","DOI":"10.1111\/all.14840"},{"key":"65292","doi-asserted-by":"crossref","unstructured":"5. Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID 19 Vaccines. Mol Ther. 2021; 29 (3): 898-900.","DOI":"10.1016\/j.ymthe.2021.01.030"},{"key":"65293","doi-asserted-by":"crossref","unstructured":"6. Risma KA, Edwards KM, Hummell DS, et al. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol. 2021; 147 (6): 2075-2082.","DOI":"10.1016\/j.jaci.2021.04.002"},{"key":"65294","doi-asserted-by":"crossref","unstructured":"7. Bianch GP. May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines? World Allergy Org J. 2021; 14 (4):1-5.","DOI":"10.1016\/j.waojou.2021.100532"},{"key":"65295","doi-asserted-by":"crossref","unstructured":"8. Rend\u00f3n-Mac\u00edas ME, Villas\u00eds-Keever M\u00c1. Fases para determinar la utilidad cl\u00ednica de las pruebas diagn\u00f3sticas. Rev Alerg Mex. 2020; 67 (3): 279-285.","DOI":"10.29262\/ram.v67i3.831"},{"key":"65296","doi-asserted-by":"crossref","unstructured":"9. Heinzerling L. The skin prick test \u2013 European standards. Clin Trans Allergy. 2013; 3 (3): 1-10.","DOI":"10.1186\/2045-7022-3-3"},{"key":"65297","doi-asserted-by":"crossref","unstructured":"10. Mitchell M, Pitlick M, Sitek A, et al. Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: Early report. Ann Allergy, Asthma Immunol. 2021; 126 (6): 735-738.","DOI":"10.1016\/j.anai.2021.03.012"},{"key":"65298","doi-asserted-by":"crossref","unstructured":"11. Mitchell M. Reply to \u2018\u2018PEG skin testing for COVID-19 allergy\u2019\u2019. J Allergy Clin Immunol Pract. 2021; 9 (4): 1765-1766.","DOI":"10.1016\/j.jaip.2021.02.015"},{"key":"65299","doi-asserted-by":"crossref","unstructured":"12. Banerji A. Wickner PG. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract. 2021; 9 (4): 1423-1437.","DOI":"10.1016\/j.jaip.2020.12.047"},{"key":"65300","doi-asserted-by":"crossref","unstructured":"13. Sellaturay P, Nasser S, Ewan P. Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis). J Allergy Clin Immunol Pract. 2021; 9 (2): 670-675.","DOI":"10.1016\/j.jaip.2020.09.029"},{"key":"65301","doi-asserted-by":"crossref","unstructured":"14. Warren CM, Snow TT, Lee AS, et al. Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open. 2021;4 (9): e2125524.","DOI":"10.1001\/jamanetworkopen.2021.25524"},{"key":"65302","doi-asserted-by":"crossref","unstructured":"15. Wolfson AR, Robinson LB, Li L, et al. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. J Allergy Clin Immunol Pract. 2021;9 (9): 3308-3320.","DOI":"10.1016\/j.jaip.2021.06.010"},{"key":"65303","doi-asserted-by":"crossref","unstructured":"16. Lim XR, Tan JWL, Chan GYL, et al. Evaluation of Patients with Vaccine Allergies Prior to mRNA-Based COVID-19 Vaccination. Vaccines (Basel). 2022; 10 (7): 1025.","DOI":"10.3390\/vaccines10071025"},{"key":"65304","doi-asserted-by":"crossref","unstructured":"17. Bruusgaard-Mouritsen MA, Jensen BM, Poulsen LK, et al. Optimizing investigation of suspected allergy to polyethylene glycols. J Allergy Clin Immunol. 2022; 149 (1): 168-175.","DOI":"10.1016\/j.jaci.2021.05.020"},{"key":"65305","doi-asserted-by":"crossref","unstructured":"18. Mortz CG, Kjaer HF, Rasmussen TH, et al. Allergy to polyethylene glycol and polysorbates in a patient cohort: Diagnostic work-up and decision points for vaccination during the COVID-19 pandemic. Clin Transl Allergy. 2022; 12 (1): 1-22.","DOI":"10.1002\/clt2.12111"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1535\/2791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1535\/2814","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1535\/2791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:51:26Z","timestamp":1783367486000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,19]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v72i4.1535","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"value":"2448-9190","type":"electronic"},{"value":"0002-5151","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}